Literature DB >> 21106580

Subclinical left ventricular dysfunction and coronary atherosclerosis in asymptomatic patients with type 2 diabetes.

Arthur J H A Scholte1, Gaetano Nucifora, Victoria Delgado, Roxana Djaberi, Mark J Boogers, Joanne D Schuijf, Antje V Kharagjitsingh, J Wouter Jukema, Ernst E van der Wall, Lucia J Kroft, Albert de Roos, Jeroen J Bax.   

Abstract

AIMS: The aim of the present study was to evaluate whether subclinical left ventricular (LV) systolic dysfunction is independently related to subclinical coronary atherosclerosis in type 2 diabetic patients and if it could provide incremental information over baseline characteristics to identify high-risk patients. METHODS AND
RESULTS: A total of 234 asymptomatic, type 2 diabetic patients without overt LV systolic dysfunction underwent coronary artery calcium (CAC) scoring and two-dimensional echocardiography. The LV global longitudinal strain (GLS) was assessed using automated function imaging. Patients with coronary atherosclerosis (CAC > 0; n = 139) had more impaired GLS when compared with patients without coronary atherosclerosis (CAC = 0; n = 95; -18.0 ± 2.8 vs. -16.3 ± 3.0%, P < 0.001). At multivariate analysis, male gender, hypertension, hypercholesterolaemia, and the LV GLS were independently associated with coronary atherosclerosis. The addition of the LV GLS to other selected independent clinical variables significantly improved the ability to predict coronary atherosclerosis in these patients (χ(2) = 58.92; P = 0.001).
CONCLUSION: Type 2 diabetic patients with coronary atherosclerosis showed a more impaired LV GLS compared with patients without coronary atherosclerosis. The presence of subclinical LV systolic dysfunction provides significant incremental value for the identification of diabetic patients having coronary atherosclerosis.

Entities:  

Mesh:

Year:  2010        PMID: 21106580     DOI: 10.1093/ejechocard/jeq165

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  6 in total

1.  Subclinical impairment of left ventricular function in diabetic patients with or without obesity: A study based on three-dimensional speckle tracking echocardiography.

Authors:  Q Wang; Y Gao; K Tan; P Li
Journal:  Herz       Date:  2014-12-11       Impact factor: 1.443

2.  Subclinical left ventricular dysfunction and silent cerebrovascular disease: the Cardiovascular Abnormalities and Brain Lesions (CABL) study.

Authors:  Cesare Russo; Zhezhen Jin; Shunichi Homma; Mitchell S V Elkind; Tatjana Rundek; Mitsuhiro Yoshita; Charles DeCarli; Clinton B Wright; Ralph L Sacco; Marco R Di Tullio
Journal:  Circulation       Date:  2013-07-31       Impact factor: 29.690

Review 3.  Incremental Value of Two Dimensional Speckle Tracking Echocardiography in the Functional Assessment and Characterization of Subclinical Left Ventricular Dysfunction.

Authors:  Prasad Gunasekaran; Sidakpal Panaich; Alexandros Briasoulis; Shaun Cardozo; Luis Afonso
Journal:  Curr Cardiol Rev       Date:  2017

4.  Exercise capacity in diabetes mellitus is predicted by activity status and cardiac size rather than cardiac function: a case control study.

Authors:  Timothy J Roberts; Andrew T Burns; Richard J MacIsaac; Andrew I MacIsaac; David L Prior; André La Gerche
Journal:  Cardiovasc Diabetol       Date:  2018-03-23       Impact factor: 9.951

Review 5.  Diabetic cardiomyopathy: prevalence, determinants and potential treatments.

Authors:  Gaurav S Gulsin; Lavanya Athithan; Gerry P McCann
Journal:  Ther Adv Endocrinol Metab       Date:  2019-03-27       Impact factor: 3.565

6.  Diabetic microvascular complications are associated with reduced global longitudinal strain independent of atherosclerotic coronary artery disease in asymptomatic patients with diabetes mellitus: a cross-sectional study.

Authors:  Gokulan Pararajasingam; Laurits Juhl Heinsen; Johanna Larsson; Thomas Rueskov Andersen; Brian Bridal Løgstrup; Søren Auscher; Jørgen Hangaard; Rasmus Møgelvang; Kenneth Egstrup
Journal:  BMC Cardiovasc Disord       Date:  2021-06-02       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.